Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5.
about
Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in miceCircumventing antivector immunity: potential use of nonhuman adenoviral vectorsAdvances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccinesProduction of adenovirus vectors and their use as a delivery system for influenza vaccines.Low seroprevalent species D adenovirus vectors as influenza vaccines.Directed evolution generates a novel oncolytic virus for the treatment of colon cancerAdenoviral vector immunity: its implications and circumvention strategies.The influence of innate and pre-existing immunity on adenovirus therapyTransduction and oncolytic profile of a potent replication-competent adenovirus 11p vector (RCAd11pGFP) in colon carcinoma cells.Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles.Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunityThe influence of delivery vectors on HIV vaccine efficacyCytotoxic T-lymphocyte escape does not always explain the transient control of simian immunodeficiency virus SIVmac239 viremia in adenovirus-boosted and DNA-primed Mamu-A*01-positive rhesus macaquesThe Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert.Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice.Cytokine response and survival of mice immunized with an adenovirus expressing Bacillus anthracis protective antigen domain 4.Current strategies and future directions for eluding adenoviral vector immunityComparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and DDevelopment of nonhuman adenoviruses as vaccine vectors.Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators.Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business".Adenovirus Vector-Derived VA-RNA-Mediated Innate Immune Responses.Selective transduction of mature DC in human skin and lymph nodes by CD80/CD86-targeted fiber-modified adenovirus-5/3.Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agentsNew insights on adenovirus as vaccine vectors.Advances and future challenges in adenoviral vector pharmacology and targeting.Adenoviral producer cellsPancreatic cancer gene therapy: from molecular targets to delivery systems.Changing faces in virology: the dutch shift from oncogenic to oncolytic viruses.Progress on adenovirus-vectored universal influenza vaccines.Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa.Applying genomic and bioinformatic resources to human adenovirus genomes for use in vaccine development and for applications in vector development for gene delivery.The prevalence of neutralising antibodies to chimpanzee adenovirus type 6 and type 7 in healthy adult volunteers, patients with chronic hepatitis B and patients with primary hepatocellular carcinoma in China.Getting genetic access to natural adenovirus genomes to explore vector diversity.Modification of the early gene enhancer-promoter improves the oncolytic potency of adenovirus 11.Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys.Barriers to systemic application of virus-based vectors in gene therapy: lessons from adenovirus type 5.Adenoviruses use lactoferrin as a bridge for CAR-independent binding to and infection of epithelial cells.Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity.Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection.
P2860
Q21092172-9452ABF7-90AD-45E7-993B-5B7258CFDB81Q26995655-BAD2B094-60D0-4774-B8DC-F4E195861DE9Q27013568-51C17DD9-4DF0-43BE-8D49-C5143A397FA5Q30226988-035F41ED-4EA7-4641-8739-70E23F758A80Q30353263-C1293330-D74B-4E16-B028-6AE71CB7F855Q33344440-8E4D55C0-0F1E-4845-A56C-5BBC8FEC494DQ33565630-638E64CD-3167-4A83-A3F7-0641EB566C00Q33655401-1186C047-9E62-4A9A-BFAA-DB1161AB1552Q33859402-637507E3-61AA-4385-BF9E-B00FFEA17F2BQ33906116-A18EA058-C12C-4483-BAEB-4351E4A35023Q33908767-4ACC4C5E-A1C7-42A9-90ED-0167DE338229Q34077543-E98EA713-CA65-4906-9D8D-D931D67CE148Q34228494-C69B2FA6-0699-4A07-8052-916AA80FD4DFQ34289823-B5487BB1-BD8E-48F5-A09A-943FBE6DE7DDQ34301004-925BCE2B-9990-4EAF-926B-5F8E691ECEC4Q34334441-278E4A9C-872D-4124-8A09-FA822EBDC37AQ34585554-42F9136A-4184-4711-BF80-812ACCD79276Q35857420-C43BFD96-B922-47B1-AF07-62421914CA8DQ36317264-9EC89F80-7715-447C-8056-0B63E8A87E82Q36323413-602132B6-17A9-40A2-BFBC-E9095989622EQ36498186-AADEF9D4-2D30-4F90-A54F-1396707F2479Q37378133-619F8906-C8E1-4AE2-AECA-904CAC3193AEQ37404870-76B9C14D-3A99-4E24-B362-EC87DD524018Q37442235-FF7B6A7F-9BA2-47F8-9B6A-C8DB8FBBC768Q37513550-E9DF9149-4EE8-4B26-A8A9-55E0C5C4F4DAQ37859842-0E70F8C0-58FD-4726-A0F8-AA9A5871610DQ37945217-1235A1D1-C11B-4346-A53D-197BB8167285Q38161331-8AC1B33F-2B57-4A92-A250-8A2596269B9FQ38241666-B12A285E-CF92-420E-8786-89EB4AEF75D9Q38421971-03C5D72E-849B-4341-8013-FB0E133822B1Q38480709-D7913591-60F2-40D9-9996-C8E734C54258Q38613979-348F7770-6E46-49FB-B429-ED8118BD90FEQ39346309-DFC21FD1-20AF-4DFA-A879-EB6E1C464DE8Q39437315-08F80D73-180D-4FA5-91A7-D20A1C794890Q39442539-AEC308DD-B0EA-436C-A33A-D3191BB0FFC7Q39612726-E54E269D-61A8-42F9-BA65-C775CCDE8427Q40103248-C91E0B51-6EE6-467D-BEAD-F4300971ECD4Q40213253-298DB2FE-87BA-436F-8DE7-6DF042A34ABBQ40333540-642D2CEB-EC48-4D54-803F-863B27378516Q41706961-7B9BB414-C66D-4B7D-9A9E-074D3B05168B
P2860
Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2004
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Novel replication-incompetent ...... non-cross-reactivity with Ad5.
@en
Novel replication-incompetent vector derived from adenovirus type 11
@nl
type
label
Novel replication-incompetent ...... non-cross-reactivity with Ad5.
@en
Novel replication-incompetent vector derived from adenovirus type 11
@nl
prefLabel
Novel replication-incompetent ...... non-cross-reactivity with Ad5.
@en
Novel replication-incompetent vector derived from adenovirus type 11
@nl
P2093
P2860
P921
P1433
P1476
Novel replication-incompetent ...... non-cross-reactivity with Ad5.
@en
P2093
Angelique Lemckert
Ben Berkhout
David Zuijdgeest
Eric Geelen
Esmeralda van der Helm
Gert Gillissen
Jerome Custers
Jorn Kaspers
Jos Grimbergen
Lennart Holterman
P2860
P304
13207-13215
P356
10.1128/JVI.78.23.13207-13215.2004
P407
P577
2004-12-01T00:00:00Z